Epigral Ltd (EPIGRAL) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Epigral achieved its highest-ever revenue of 2,565 crores and sales volumes in FY25.
- Profit after tax (PAT) reached a record high of 357 crores, representing an 82% growth.
- Revenue from derivatives and specialty business increased to 54% of total revenue, up from 45% in FY24.
- Captive chlorine consumption reached 72% in FY25.
- The company aims to increase revenue contribution from derivatives and specialty business to 70% with planned expansions.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.